Clinical Research Directory
Browse clinical research sites, groups, and studies.
Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency
Sponsor: Avni Joshi
Summary
The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.
Official title: Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2023-04-12
Completion Date
2026-12
Last Updated
2026-01-06
Healthy Volunteers
No
Interventions
Fisetin
20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29
Placebo
Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States